Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in alzheimer's disease: The omegad study

Dementia and Geriatric Cognitive Disorders

Volumn 27, Issue 5, 2009, Pages 481-490

  Freund Levi, Yvonne ^a,b   Hjorth, Erik ^a   Lindberg, Catharina ^a   Cederholm, Tommy ^c   Faxen Irving, Gerd ^a   Vedin, Inger ^b   Palmblad, Jan ^b   Wahlund, Lars Olof ^a   Schultzberg, Marianne ^a   Basun, Hans ^c   Eriksdotter Jönhagen, Maria ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

3 fatty acids; Alzheimer's disease; Cerebrospinal fluid; Cytokines; Inflammation

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; FISH OIL; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 6; OMEGA 3 FATTY ACID; PLACEBO; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; MALE; NEUROPSYCHOLOGICAL TESTS; TAU PROTEINS;

EID: 65549164405     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218081     Document Type: Article

References (54)

1. Tabet N, Feldman H: Ibuprofen for Alzheimer's disease Cochrane Database Syst. Rev 2003Art No: CD004031.
2. Meinert CL, Breitner JC: Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). Alzheimers Dement 2008;4:(suppl 1):S7-S14.
3. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM: Inflammatory proteins in plasma and the risk of dementia. The Rotterdam Study. Arch Neurol 2004;61:668-672.
4. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ: Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005;2:1-10.
5. Farfara D, Lifschitz V, Frenkel D: Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Med 2008;12:762-780.
6. Schultzberg M, Lindberg C, Aronsson Forslin Å, Hjorth E, Spulber SD, Oprica M: Inflammation in the nervous system-physiological and pathophysiological aspects. Physiol Behav 2007;92:121-128.
7. Mrak RE, Griffin WS: Potential Inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 2005;8:369-375.
8. Tarkowski E, Blennow K, Wallin A,Tarkowski A: Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999;19:223-230.
9. Tobinick E, Gross H, Weinberger A, Cohen H: TNF-α modulation for treatment of Alzheimer's disease:6-month pilot study. Med Gen Med 2006;8:25.
10. Scheff SW, Price DA, Schmitt FA, Mufson EJ: Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006;27:1372-1384.
11. Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautchsy SA: Prevention of Alzheimer's disease: Omega 3fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 2005;26S1:133-136.
12. Kalmijn S, Launer LJ, Alewijn O, Witteman JC, Hofman A, Breteler MM: Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997;42:776-782.
13. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM: A diet enriched with the omega-3fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25:3032-3040.
14. Söderberg M, Edlund C, Kristensson K, Dallner G: Fatty acid composition of brain phospholipids in aging in Alzheimer's disease. Lipids 1991;26:421-425.
15. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH: Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000;35:1305-1312.
16. Serhan CN: Mediator lipidomics. Prostaglandins Other Lipid Mediat 2005;77:4-14.
17. Mukherjee PK, Chawla A, Loayza MS, Bazan NG: Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot Essent Fat ty Acids 2007;77:233-238.
18. Calon F, Cole G: Neuroprotective action of omega-3polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Review. Prostaglandins Leukot Essent Fatty Acids 2007;77:287-293.
19. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG: A role for docosahexaenoic acid-derived neuroprotectin D1in neural cell survival and Alzheimer disease. J Clin Invest 2005;115:2774-2783.
20. Farooqui AA, Ong WY, Horrocks LA, Cheng P, Farooqui T: Comparison of biochemical effects of statins and fish oil in the brain: the battle of the titans. Brain Res Rev 2007;56:443-471.
21. Calderon F, Kim HY: Role of RXR in neurite outgrowth induced by docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 2007;77:227-232.
22. Issa AM, Mojica WA, Morton SC, Traina S, Newberry SJ, Hilton LG, Garland RH, MacLean CH: The efficacy of omega-3fatty acids on cognitive functions in aging and dementia: a systematic review. Dement Geriatr Cogn Disord 2006;21:88-96.
23. Calder PC: Dietary modification of inflammation with lipids. Review. Proc Nutr Soc 2002;61:345-358.
24. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ: Development of cognitive instruments for use in clinical trials of antidementia drugs; additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2): S13-S21.
25. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
26. Freund-Levi Y, Eriksdotter Jönhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J: Omega-3fatty acid treatment in 174patients with mild to moderate Alzheimer's disease: OmegAD Study. Arch Neurol 2006;63:1402-1408.
27. Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter Jönhagen M: Omega-3supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008;23:161-169.
28. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F: Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005;4:371-380.
29. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
30. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
31. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
32. Blennow K, Wallin A, Ågren H, Spenger C, Siegfrid J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's Disease? Mol Chem Neuropathol 1995;26:231-245.
33. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van der Perre B, Sjogren M, Andreasen N, Blennow K: Quantification of tau phosphorylated at threonine 181in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
34. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid β-amyloid (1-42) in Alzheimer disease and stability during the course of the disease. Arch Neurol 1999;56:673-680.
35. Boberg M, Croon LB, Gustafsson IB, Vessby B: Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway. Clin Sci 1985;68:581-587.
36. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990;31:545-548.
37. Laws SM, Hone E, Gandy S, Martins RN: Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003;84:1215-1236.
38. Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA: NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Review. Ann NY Acad Sci 2004;1035:68-84.
39. Feldman H, Jacova C: Primary prevention and delay of onset of AD and dementia. Review. Can J Neurol Sci 2007;34:S84-S89.
40. Venkatraman JT, Chu WC: Effects of dietary omega-3and omega-6lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr 1999;18:602-613.
41. Garlind A, Brauner A, Höjeberg B, Basun H, Schultzberg M: Soluble interleukin-1receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res 1999;826:112-116.
42. Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF: Cerebrospinal fluid tau, Aβ1-42and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett 2005;383:12-16.
43. Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, Volpato S, Atti AR, Ble' A, Fellin R: Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007;41:686-693.
44. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks L, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007;13:1359-1362.
45. Tabet N: Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age Ageing 2006;35:336-338.
46. Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D: Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1β and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 2005;40:165-171.
47. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T: Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006;56:159-164.
48. Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI: Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life. Int J Neurosci 1996;87:141-149.
49. NIH website. ClinicalTrials.gov. DHA an omega 3fatty acid in slowing the progression of Alzheimer's disease 2008.
50. Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Sensitivity, specificity and stability of CSF-tau in AD in community-based patient sample. Neurology 1999;53:1488-1494.
51. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, Lindau M, Eriksdotter Jönhagen M: Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 2008;29:1466-1473.
52. Oprica M, Hjorth E, Spulber S, Popescu BO, Ankarcrona M, Winblad B, Schultzberg M: Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1receptor antagonist. J Cell Mol Med 2007;11:810-825.
53. Lindberg C, Chromek M, Ahrengart L, Brauner A, Schultzberg M, Garlind A: Soluble interleukin-1receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochem 2005;46:551-557.
54. Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF: Regulated intramembrane proteolysis of the interleukin-1 receptor II by α-, β-and Χ-secretase. J Biol Chem 2007;282:11982-11995.